Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) Will Post Quarterly Sales of $57.44 Million

Brokerages predict that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will post $57.44 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Sucampo Pharmaceuticals’ earnings. The lowest sales estimate is $56.61 million and the highest is $58.60 million. Sucampo Pharmaceuticals posted sales of $57.87 million in the same quarter last year, which suggests a negative year over year growth rate of 0.7%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Sucampo Pharmaceuticals will report full-year sales of $57.44 million for the current year. For the next year, analysts anticipate that the company will report sales of $243.33 million per share, with estimates ranging from $234.39 million to $258.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company had revenue of $59.90 million for the quarter, compared to the consensus estimate of $56.44 million. During the same quarter in the previous year, the business earned $0.24 EPS. Sucampo Pharmaceuticals’s revenue was up 15.3% compared to the same quarter last year.

Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Tuesday. UBS AG decreased their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, October 12th. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $14.00 to $12.00 in a research note on Tuesday, October 3rd. Leerink Swann assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Maxim Group reissued a “buy” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $16.50.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) Will Post Quarterly Sales of $57.44 Million” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://ledgergazette.com/2017/10/19/zacks-brokerages-anticipate-sucampo-pharmaceuticals-inc-scmp-will-post-quarterly-sales-of-57-44-million.html.

In related news, insider Jones W. Bryan bought 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now owns 4,700 shares in the company, valued at approximately $49,820. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.

Several large investors have recently modified their holdings of the company. Krensavage Asset Management LLC increased its position in shares of Sucampo Pharmaceuticals by 0.6% during the second quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after acquiring an additional 16,570 shares during the period. LSV Asset Management increased its holdings in Sucampo Pharmaceuticals by 1.9% during the second quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock valued at $25,099,000 after buying an additional 44,000 shares during the period. Vanguard Group Inc. increased its holdings in Sucampo Pharmaceuticals by 13.0% during the second quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 189,561 shares during the period. Dimensional Fund Advisors LP increased its holdings in Sucampo Pharmaceuticals by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after buying an additional 15,528 shares during the period. Finally, NEA Management Company LLC purchased a new position in Sucampo Pharmaceuticals during the second quarter valued at approximately $13,214,000. 55.46% of the stock is currently owned by institutional investors and hedge funds.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 0.49% on Thursday, hitting $10.15. The company’s stock had a trading volume of 102,448 shares. The firm has a 50 day moving average of $11.50 and a 200 day moving average of $10.69. The firm’s market cap is $470.20 million. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings

On average, analysts expect that Sucampo Pharmaceuticals will report full-year sales of $57.44 million for the current year. For the next year, analysts anticipate that the company will report sales of $243.33 million per share, with estimates ranging from $234.39 million to $258.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company had revenue of $59.90 million for the quarter, compared to the consensus estimate of $56.44 million. During the same quarter in the previous year, the business earned $0.24 EPS. Sucampo Pharmaceuticals’s revenue was up 15.3% compared to the same quarter last year.

Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Tuesday. UBS AG decreased their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, October 12th. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $14.00 to $12.00 in a research note on Tuesday, October 3rd. Leerink Swann assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Maxim Group reissued a “buy” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $16.50.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) Will Post Quarterly Sales of $57.44 Million” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://ledgergazette.com/2017/10/19/zacks-brokerages-anticipate-sucampo-pharmaceuticals-inc-scmp-will-post-quarterly-sales-of-57-44-million.html.

In related news, insider Jones W. Bryan bought 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now owns 4,700 shares in the company, valued at approximately $49,820. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.

Several large investors have recently modified their holdings of the company. Krensavage Asset Management LLC increased its position in shares of Sucampo Pharmaceuticals by 0.6% during the second quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after acquiring an additional 16,570 shares during the period. LSV Asset Management increased its holdings in Sucampo Pharmaceuticals by 1.9% during the second quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock valued at $25,099,000 after buying an additional 44,000 shares during the period. Vanguard Group Inc. increased its holdings in Sucampo Pharmaceuticals by 13.0% during the second quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 189,561 shares during the period. Dimensional Fund Advisors LP increased its holdings in Sucampo Pharmaceuticals by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock valued at $16,487,000 after buying an additional 15,528 shares during the period. Finally, NEA Management Company LLC purchased a new position in Sucampo Pharmaceuticals during the second quarter valued at approximately $13,214,000. 55.46% of the stock is currently owned by institutional investors and hedge funds.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 0.49% on Thursday, hitting $10.15. The company’s stock had a trading volume of 102,448 shares. The firm has a 50 day moving average of $11.50 and a 200 day moving average of $10.69. The firm’s market cap is $470.20 million. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply